spacer
home > ebr > winter 2002 > non-viral gene delivery methods
PUBLICATIONS
European Biopharmaceutical Review

Non-Viral Gene Delivery Methods

The last decade has seen substantial progress in the development and application of non-viral vectors in gene therapy. Infectious disease, genetic defects and even traumatic injury may someday be treated with gene therapy and gene transfer strategies. The potential impact of this new technology on human disease has produced optimism and expectation for scientists and lay people alike. As more effort is directed at developing the potential of this technology, it has become evident that the success or failure of gene therapeutic approaches will centre on the ability to manipulate and control the process of genetic transfer into somatic cells.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Günter Kraus, Vice President of Research and Development at amaxa GmbH Dr Günter Kraus is Vice President of Research and Development at amaxa GmbH, a German biotechnology company based in Cologne. Prior to joining the company in 2002, he spent 12 years at two academic institutions in the USA, where he was a Principal Investigator into DNA-based HIV vaccines, and received a prestigious amfAR award and a Susan G. Komen Foundation breast cancer research award. Günter holds a PhD in Microbiology from the JohannWolfgang-Goethe University, Germany and wrote his thesis on infectious diseases at the Paul-Ehrlich Institute.
He has extensive knowledge of the development of viral and non-viral gene delivery systems and in the field of gene therapy. He has also co-authored numerous research articles in peer reviewed scientific journals and several US-issued patents.

spacer
Dr Günter Kraus
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers
 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement